Mild SARS-CoV-2 infection in vulnerable patients : implementation of a clinical pathway for early treatment
Copyright © 2022 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier España, S.L.U. All rights reserved..
INTRODUCTION: The objective of this report is to describe the clinical pathway for early treatment of patients with acute SARS-CoV-2 infection and to evaluate the first results of its implementation.
METHODS: This is a descriptive and retrospective study of the implementation of a clinical pathway of treatment in outpatients (January 1 to June 30 2022). Clinical pathway: detection and referral systems from Primary Care, Emergency services, hospital specialities and an automated detection system; clinical evaluation and treatment administration in the COVID-19 day-hospital and subsequent clinical follow-up. Explanatory variables: demographics, comorbidity, vaccination status, referral pathways and treatment administration.
OUTCOME VARIABLES: hospitalization and death with 30 days, grade 2-3 toxicity related to treatment.
RESULTS: Treatment was administered to 262 patients (53,4% women, median age 60 years). The treatment indication criteria were immunosupression (68,3%), and the combination of age, vaccination status and comorbidity in the rest 47,3% of the patients s received remdesivir, 35,9% nirmatrelvir/ritonavir, 13,4% sotrovimab and 2,4% combined treatment with a median of 4 days after symptom onset. Hospital admission was required for 6,1% of the patients, 3,8% related to progression COVID-19. No patient died. Toxicity grade 2-3 toxicity was reported in 18,7%, 89,8% dysgeusia and metallic tasted related nirmatrelvir/ritonavir. Seven patients discontinued treatment due to toxicity.
CONCLUSION: The creation and implementation of a clinical pathway for non-hospitalized patients with SARS-CoV-2 infection is effective and it allows early accessibility and equity of currently available treatments.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Enfermedades infecciosas y microbiologia clinica (English ed.) - 42(2024), 4 vom: 05. Apr., Seite 195-201 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pinargote-Celorio, Héctor [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.04.2024 Date Revised 08.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.eimce.2023.03.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355087618 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355087618 | ||
| 003 | DE-627 | ||
| 005 | 20240408232015.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.eimce.2023.03.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1369.xml |
| 035 | |a (DE-627)NLM355087618 | ||
| 035 | |a (NLM)37003904 | ||
| 035 | |a (PII)S2529-993X(23)00090-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pinargote-Celorio, Héctor |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mild SARS-CoV-2 infection in vulnerable patients |b implementation of a clinical pathway for early treatment |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2024 | ||
| 500 | |a Date Revised 08.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a INTRODUCTION: The objective of this report is to describe the clinical pathway for early treatment of patients with acute SARS-CoV-2 infection and to evaluate the first results of its implementation | ||
| 520 | |a METHODS: This is a descriptive and retrospective study of the implementation of a clinical pathway of treatment in outpatients (January 1 to June 30 2022). Clinical pathway: detection and referral systems from Primary Care, Emergency services, hospital specialities and an automated detection system; clinical evaluation and treatment administration in the COVID-19 day-hospital and subsequent clinical follow-up. Explanatory variables: demographics, comorbidity, vaccination status, referral pathways and treatment administration | ||
| 520 | |a OUTCOME VARIABLES: hospitalization and death with 30 days, grade 2-3 toxicity related to treatment | ||
| 520 | |a RESULTS: Treatment was administered to 262 patients (53,4% women, median age 60 years). The treatment indication criteria were immunosupression (68,3%), and the combination of age, vaccination status and comorbidity in the rest 47,3% of the patients s received remdesivir, 35,9% nirmatrelvir/ritonavir, 13,4% sotrovimab and 2,4% combined treatment with a median of 4 days after symptom onset. Hospital admission was required for 6,1% of the patients, 3,8% related to progression COVID-19. No patient died. Toxicity grade 2-3 toxicity was reported in 18,7%, 89,8% dysgeusia and metallic tasted related nirmatrelvir/ritonavir. Seven patients discontinued treatment due to toxicity | ||
| 520 | |a CONCLUSION: The creation and implementation of a clinical pathway for non-hospitalized patients with SARS-CoV-2 infection is effective and it allows early accessibility and equity of currently available treatments | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Clinical pathway | |
| 650 | 4 | |a Nirmatrelvir/ritonavir | |
| 650 | 4 | |a Non-hospitalized treatment | |
| 650 | 4 | |a Remdesivir | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Sotrovimab | |
| 650 | 4 | |a Tratamiento no hospitalizados | |
| 650 | 4 | |a Vía clínica | |
| 650 | 7 | |a nirmatrelvir |2 NLM | |
| 650 | 7 | |a 7R9A5P7H32 |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 650 | 7 | |a Lactams |2 NLM | |
| 650 | 7 | |a Leucine |2 NLM | |
| 650 | 7 | |a GMW67QNF9C |2 NLM | |
| 650 | 7 | |a Nitriles |2 NLM | |
| 650 | 7 | |a Proline |2 NLM | |
| 650 | 7 | |a 9DLQ4CIU6V |2 NLM | |
| 700 | 1 | |a Otero-Rodríguez, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a González-de-la-Aleja, Pilar |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Díaz, Juan-Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Climent, Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a Chico-Sánchez, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Riera, Gerónima |e verfasserin |4 aut | |
| 700 | 1 | |a Llorens, Pere |e verfasserin |4 aut | |
| 700 | 1 | |a Aparicio, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Montiel, Inés |e verfasserin |4 aut | |
| 700 | 1 | |a Boix, Vicente |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno-Pérez, Óscar |e verfasserin |4 aut | |
| 700 | 1 | |a Ramos-Rincón, José-Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Merino, Esperanza |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Enfermedades infecciosas y microbiologia clinica (English ed.) |d 2012 |g 42(2024), 4 vom: 05. Apr., Seite 195-201 |w (DE-627)NLM220666776 |x 2529-993X |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2024 |g number:4 |g day:05 |g month:04 |g pages:195-201 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.eimce.2023.03.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2024 |e 4 |b 05 |c 04 |h 195-201 | ||